← Back to patent-cliff list
PF-07328948
Tier C — Watch / tradePF-07328948
Pfizer Inc.
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：BCKDK
Indications (approved)：Heart failure, Renal impairment, Hepatic function decline
Regional status
US
Phase II
2025-06-19
EU
Phase II
2025-06-19
China
Phase II
2025-06-19
Japan
Phase II
2025-06-19
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of PF-07328948?
Approved indications include: Heart failure, Renal impairment, Hepatic function decline.
When does the PF-07328948 patent expire?
No public expiry year is available for PF-07328948 yet; this page updates once verified.
How do I get a quote for PF-07328948 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-30